Read by QxMD icon Read

British Journal of Cancer

Harmke J Groot, Jourik A Gietema, Berthe M P Aleman, Luca Incrocci, Ronald de Wit, J Alfred Witjes, Gerard Groenewegen, Peter de Brouwer, Otto W M Meijer, Maarten C C M Hulshof, Hetty A van den Berg, Tineke J Smilde, Ben G L Vanneste, Maureen J Aarts, Alphonsus C M van den Bergh, J Martijn Kerst, Alexandra W van den Belt-Dusebout, Sjoukje Lubberts, Katarzina Jóźwiak, Simon Horenblas, Flora E van Leeuwen, Michael Schaapveld
BACKGROUND: While the risk of diabetes is increased following radiation exposure to the pancreas among childhood cancer survivors, its association among testicular cancer (TC) survivors has not been investigated. METHODS: Diabetes risk was studied in 2998 1-year TC survivors treated before 50 years of age with orchidectomy with/without radiotherapy between 1976 and 2007. Diabetes incidence was compared with general population rates. Treatment-specific risk of diabetes was assessed using a case-cohort design...
October 9, 2018: British Journal of Cancer
Burak Uzunparmak, Ibrahim H Sahin
No abstract text is available yet for this article.
October 9, 2018: British Journal of Cancer
Antonia K Roseweir, Donald C McMillan, Joanne Edwards
No abstract text is available yet for this article.
October 9, 2018: British Journal of Cancer
Alina V Brenner, Peter D Inskip, Jennifer Rusiecki, Charles S Rabkin, Joshua Engels, Ruth M Pfeiffer
BACKGROUND: There is growing evidence that history of allergic or autoimmune disease is associated with reduced risk of glioma, but few prospective studies have explored the biological basis. To assess associations with immune conditions and levels of 14 cytokines in serial prediagnostic serum samples, we conducted a study of glioma/brain cancer nested in a cohort of active component military personnel. METHODS: A total of 457 case-control sets were ascertained from the Department of Defense (DoD) Automated Central Tumour Registry, Defense Medical Surveillance System (DMSS) database, and DoD Serum Repository...
October 9, 2018: British Journal of Cancer
Riikka Johanna Niemi, Elena Ioana Braicu, Hagen Kulbe, Kaisa Maria Koistinen, Jalid Sehouli, Ulla Puistola, Johanna Unelma Mäenpää, Mika Hilvo
BACKGROUND: Previous results obtained from serum samples of late-stage, high-grade serous ovarian carcinoma patients showed large alterations in lipid metabolism. To validate and extend the results, we studied lipidomic changes in early-stage ovarian tumours. In addition to serous ovarian cancer, we investigated whether these changes occur in mucinous and endometrioid histological subtypes as well. METHODS: Altogether, 354 serum or plasma samples were collected from three centres, one from Germany and two from Finland...
October 8, 2018: British Journal of Cancer
Elin Sjöberg, Magnus Frödin, John Lövrot, Artur Mezheyeuski, Martin Johansson, Ulrika Harmenberg, Lars Egevad, Per Sandström, Arne Östman
BACKGROUND: The role of B-lymphocytes in solid tumours is unclear. Tumour biology studies have implied both anti- and pro-tumoural effects and prognostic studies have mainly linked B-cells to increased survival. This study aimed to analyse the clinical relevance of B-lymphocytes in renal cell cancer (RCC), where information on the prognostic impact is lacking. METHODS: Following immunohistochemistry (IHC) stainings with a CD20 antibody, density of CD20+ B-cells was quantified in an RCC discovery- and validation cohort...
October 8, 2018: British Journal of Cancer
Tracy L Rose, David D Chism, Ajjai S Alva, Allison M Deal, Susan J Maygarden, Young E Whang, Jordan Kardos, Anthony Drier, Ethan Basch, Paul A Godley, Mary W Dunn, William Y Kim, Matthew I Milowsky
BACKGROUND: The majority of urothelial cancers (UC) harbor alterations in retinoblastoma (Rb) pathway genes that can lead to loss of Rb tumour suppressor function. Palbociclib is an oral, selective inhibitor of CDK 4/6 that restores Rb function and promotes cell cycle arrest. METHODS: In this phase II trial, patients with metastatic platinum-refractory UC molecularly selected for p16 loss and intact Rb by tumour immunohistochemistry received palbociclib 125 mg p...
October 8, 2018: British Journal of Cancer
Malgorzata Bajor, Agata O Zych, Agnieszka Graczyk-Jarzynka, Angelika Muchowicz, Malgorzata Firczuk, Lech Trzeciak, Pawel Gaj, Antoni Domagala, Marta Siernicka, Agnieszka Zagozdzon, Pawel Siedlecki, Monika Kniotek, Patrick C O'Leary, Jakub Golab, Radoslaw Zagozdzon
BACKGROUND: Our previous work has shown peroxiredoxin-1 (PRDX1), one of major antioxidant enzymes, to be a biomarker in human breast cancer. Hereby, we further investigate the role of PRDX1, compared to its close homolog PRDX2, in mammary malignant cells. METHODS: CRISPR/Cas9- or RNAi-based methods were used for genetic targeting PRDX1/2. Cell growth was assessed by crystal violet, EdU incorporation or colony formation assays. In vivo growth was assessed by a xenotransplantation model...
October 5, 2018: British Journal of Cancer
Lindsay A Williams, Lauren Mills, Anthony J Hooten, Erica Langer, Michelle Roesler, A Lindsay Frazier, Mark Krailo, Heather H Nelson, Jessica Bestrashniy, James F Amatruda, Jenny N Poynter
BACKGROUND: Abnormal DNA methylation may be important in germ cell tumour (GCT) aetiology, as germ cells undergo complete epigenetic reprogramming during development. GCTs show differences in global and promoter methylation patterns by histologic subtype. We conducted an epigenome-wide study to identify methylation differences by GCT histology. METHODS: Using the Illumina HumanMethylation450K array we measured methylation in 154 paediatric GCTs (21 germinomas/seminomas/dysgerminoma, 70 yolk sac tumours [YST], 9 teratomas, and 54 mixed histology tumours)...
October 5, 2018: British Journal of Cancer
Silvia Halim, Elke K Markert, Alexei Vazquez
BACKGROUND: Human cancers can be classified based on gene signatures quantifying the degree of cell proliferation and tissue remodelling (PR). However, the specific factors that drive the increased tissue remodelling in tumours are not fully understood. Here we address this question using colorectal cancer as a case study. METHODS: We reanalysed a reported cohort of colorectal cancer patients. The patients were stratified based on gene signatures of cell proliferation and tissue remodelling...
October 5, 2018: British Journal of Cancer
Ping Wang, Viktor Magdolen, Christof Seidl, Julia Dorn, Enken Drecoll, Matthias Kotzsch, Feng Yang, Manfred Schmitt, Oliver Schilling, Anja Rockstroh, Judith Ann Clements, Daniela Loessner
BACKGROUND: Tissue kallikrein-related peptidases 4, 5, 6 and 7 (KLK4-7) strongly increase the malignancy of ovarian cancer cells. Deciphering their downstream effectors, we aimed at finding new potential prognostic biomarkers and treatment targets for ovarian cancer patients. KLK4-7-transfected (OV-KLK4-7) and vector-control OV-MZ-6 (OV-VC) ovarian cancer cells were established to select differentially regulated factors. METHODS: With three independent approaches, PCR arrays, genome-wide microarray and proteome analyses, we identified 10 candidates (MSN, KRT19, COL5A2, COL1A2, BMP5, F10, KRT7, JUNB, BMP4, MMP1)...
October 5, 2018: British Journal of Cancer
Dinja T Kruger, Karin J Beelen, Mark Opdam, Joyce Sanders, Vincent van der Noort, Epie Boven, Sabine C Linn
BACKGROUND: The phosphatidylinositol-3-kinase (PI3K) and/or mitogen-activated protein kinase (MAPK) pathways are frequently activated in breast cancer which can result in antioestrogen resistance. Single protein markers failed to be introduced into clinical practice. We, therefore, aimed to find a better read-out of activation of the PI3K and MAPK pathways in ER+/HER2- breast cancer. Assessment of seven PI3K/MAPK proteins might better reflect pathway activation and distinguish patients without adjuvant tamoxifen benefit...
October 5, 2018: British Journal of Cancer
Hermann Brenner, Chen Chen
Colorectal cancer (CRC) is both one of the most common and one of the most preventable cancers globally, with powerful but strongly missed potential for primary, secondary and tertiary prevention. CRC incidence has traditionally been the highest in affluent Western countries, but it is now increasing rapidly with economic development in many other parts of the world. CRC shares several main risk factors, such as smoking, excessive alcohol consumption, physical inactivity and being overweight, with other common diseases; therefore, primary prevention efforts to reduce these risk factors are expected to have multiple beneficial effects that extend beyond CRC prevention, and should have high public health impact...
October 4, 2018: British Journal of Cancer
Victor Moreno, M Henar Alonso, Adrià Closa, Xavier Vallés, Anna Diez-Villanueva, Laura Valle, Sergi Castellví-Bel, Rebeca Sanz-Pamplona, Adriana Lopez-Doriga, David Cordero, Xavier Solé
BACKGROUND: Genome-wide association studies on colorectal cancer have identified more than 60 susceptibility loci, but for most of them there is no clear knowledge of functionality or the underlying gene responsible for the risk modification. Expression quantitative trail loci (eQTL) may provide functional information for such single nucleotide polymorphisms (SNPs). METHODS: We have performed detailed eQTL analysis specific for colon tissue on a series of 97 colon tumours, their paired adjacent normal mucosa and 47 colon mucosa samples donated by healthy individuals...
October 4, 2018: British Journal of Cancer
Estela Dámaso, Adela Castillejo, María Del Mar Arias, Julia Canet-Hermida, Matilde Navarro, Jesús Del Valle, Olga Campos, Anna Fernández, Fátima Marín, Daniela Turchetti, Juan de Dios García-Díaz, Conxi Lázaro, Maurizio Genuardi, Daniel Rueda, Ángel Alonso, Jose Luis Soto, Megan Hitchins, Marta Pineda, Gabriel Capellá
BACKGROUND: Constitutional MLH1 epimutations are characterised by monoallelic methylation of the MLH1 promoter throughout normal tissues, accompanied by allele-specific silencing. The mechanism underlying primary MLH1 epimutations is currently unknown. The aim of this study was to perform an in-depth characterisation of constitutional MLH1 epimutations targeting the aberrantly methylated region around MLH1 and other genomic loci. METHODS: Twelve MLH1 epimutation carriers, 61 Lynch syndrome patients, and 41 healthy controls, were analysed by Infinium 450 K array...
October 4, 2018: British Journal of Cancer
Luis G Carvajal-Carmona
No abstract text is available yet for this article.
October 4, 2018: British Journal of Cancer
Richard G Stevens
No abstract text is available yet for this article.
October 3, 2018: British Journal of Cancer
Joaquim Bellmunt, Aly-Khan A Lalani, Sussana Jacobus, Stephanie A Wankowicz, Laura Polacek, David Y Takeda, Lauren C Harshman, Nikhil Wagle, Irene Moreno, Kevin Lundgren, Dominick Bossé, Eliezer M Van Allen, Toni K Choueiri, Jonathan E Rosenberg
BACKGROUND: Metastatic urothelial carcinoma (mUC) is a genomically diverse disease with known alterations in the mTOR pathway and tyrosine kinases including FGFR. We investigated the efficacy and safety of combination treatment with everolimus and pazopanib (E/P) in genomically profiled patients with mUC. METHODS: mUC patients enrolled on a Phase I dose escalation study and an expansion cohort treated with E/P were included. The primary end point was objective response rate (ORR); secondary end points were safety, duration of response (DOR), progression-free survival (PFS) and overall survival (OS)...
September 17, 2018: British Journal of Cancer
David S Ziegler, Marie Wong, Chelsea Mayoh, Amit Kumar, Maria Tsoli, Emily Mould, Vanessa Tyrrell, Dong-Anh Khuong-Quang, Mark Pinese, Velimir Gayevskiy, Richard J Cohn, Loretta M S Lau, Mark Reynolds, Michael C Cox, Andrew Gifford, Michael Rodriguez, Mark J Cowley, Paul G Ekert, Glenn M Marshall, Michelle Haber
Genes encoding TRK are oncogenic drivers in multiple tumour types including infantile fibrosarcoma, papillary thyroid cancer and high-grade gliomas (HGG). TRK fusions have a critical role in tumourigenesis in 40% of infant HGG. Here we report the first case of a TRK fusion-driven HGG treated with larotrectinib-the first selective pan-TRK inhibitor in clinical development. This 3-year-old girl had failed multiple therapies including chemotherapy and radiotherapy. Tumour profiling confirmed an ETV6-NTRK3 fusion...
September 17, 2018: British Journal of Cancer
Hongdan Li, Feng Li
BACKGROUND: Bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) are progenitor cells shown to migrate to the tumour and participate in the tumour microenvironment. BM-MSCs play important roles in tumour processes through the release of cytokines or exosomes; however, how BM-MSCs influence the stemness of CSCs in colon cancer cells remains poorly understood. METHODS: We isolated exosomes from BM-MSCs and used these exosomes to treat colon cancer cells (HCT-116, HT-29 and SW-480)...
September 17, 2018: British Journal of Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"